MX2022013164A - Tratamiento del sindrome de dificultad respiratoria aguda y otros trastornos que implican una tormenta de citoquinas mediante el uso de inhibidores de btk. - Google Patents

Tratamiento del sindrome de dificultad respiratoria aguda y otros trastornos que implican una tormenta de citoquinas mediante el uso de inhibidores de btk.

Info

Publication number
MX2022013164A
MX2022013164A MX2022013164A MX2022013164A MX2022013164A MX 2022013164 A MX2022013164 A MX 2022013164A MX 2022013164 A MX2022013164 A MX 2022013164A MX 2022013164 A MX2022013164 A MX 2022013164A MX 2022013164 A MX2022013164 A MX 2022013164A
Authority
MX
Mexico
Prior art keywords
respiratory distress
acute respiratory
syndrome
distress syndrome
treatment
Prior art date
Application number
MX2022013164A
Other languages
English (en)
Spanish (es)
Inventor
Dolca Thomas
Claire Langrish
Stefani Wolff
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022013164A publication Critical patent/MX2022013164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022013164A 2020-04-22 2021-04-21 Tratamiento del sindrome de dificultad respiratoria aguda y otros trastornos que implican una tormenta de citoquinas mediante el uso de inhibidores de btk. MX2022013164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
MX2022013164A true MX2022013164A (es) 2022-11-30

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013164A MX2022013164A (es) 2020-04-22 2021-04-21 Tratamiento del sindrome de dificultad respiratoria aguda y otros trastornos que implican una tormenta de citoquinas mediante el uso de inhibidores de btk.

Country Status (12)

Country Link
US (1) US20230158031A1 (enExample)
EP (1) EP4138836A1 (enExample)
JP (2) JP2023522693A (enExample)
KR (1) KR20230015346A (enExample)
CN (1) CN115443136A (enExample)
AU (1) AU2021261327A1 (enExample)
BR (1) BR112022020974A2 (enExample)
CA (1) CA3175788A1 (enExample)
IL (1) IL297316A (enExample)
MX (1) MX2022013164A (enExample)
TW (1) TW202206076A (enExample)
WO (1) WO2021216696A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Also Published As

Publication number Publication date
BR112022020974A2 (pt) 2022-12-06
AU2021261327A1 (en) 2022-12-22
WO2021216696A1 (en) 2021-10-28
CN115443136A (zh) 2022-12-06
TW202206076A (zh) 2022-02-16
JP2026027386A (ja) 2026-02-18
KR20230015346A (ko) 2023-01-31
IL297316A (en) 2022-12-01
JP2023522693A (ja) 2023-05-31
CA3175788A1 (en) 2021-10-28
US20230158031A1 (en) 2023-05-25
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JP2024042014A5 (ja) ゲームコントローラセット、および、システム
MX2022013164A (es) Tratamiento del sindrome de dificultad respiratoria aguda y otros trastornos que implican una tormenta de citoquinas mediante el uso de inhibidores de btk.
ZA202104678B (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
WO2024026433A3 (en) Novel dpp1 inhibitors and uses thereof
IL326350A (en) Benzopyridinones and benzopyrimidinones as PI3K inhibitors
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
AU2024314618A1 (en) Pi3k inhibitors and use thereof
EP4469449A4 (en) PARP1 INHIBITORS AND THEIR USES
IL314009A (en) PARP1 inhibitors and their uses
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
LT4284512T (lt) Citokinų išsiskyrimo sindromo gydymo kompozicijos ir būdai
CA3251244A1 (en) PI3K-ALPHA INHIBITORS AND THEIR METHODS OF USE
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
EP4556072A3 (en) Compositions for monocyte and macrophage polarization and methods of use
EP4179069A4 (en) METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME
CL2023000679A1 (es) Métodos y composiciones relacionados con la evaluación de afecciones inflamatorias relacionadas con la fecundidad
WO2022047225A3 (en) Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases
EP4436607A4 (en) REDUCTION OF INFLAMMATORY CYTOKINES AND MITIGATION OF COVID-19 WITH VANDETANIB
EP4153192B8 (en) Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
Lodge et al. S114 Hypoxia drives neutrophil-mediated endothelial damage in copd
HK40084367A (en) Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors
CL2025003113A1 (es) Uso de milvexian para tratamiento o prevención de eventos cerebrovasculares adversos o cardiovasculares adversos.